Cancer has long been one of the most feared conditions that people have had to deal with. At the present there is no cure for cancer and treatments range from surgery to radiation with none being a guaranteed cure. But now there is one drug that has shown some promise in human testing.
Human testing of a cancer killing drug are under way and have shown some apparent positive results. The drug is called BXQ-350 and like many of the worlds greatest discoveries, was found quite by accident.
The discovery can be traced to a day in 2002 in a laboratory at Cincinnati Children’s Hospital Medical Center. On that day a researcher named Xiaoyang Qi was studying the action of a human protein on mice. Instead of seeing what he may have expected in the microscope, the researcher was surprised to see that the protein had fused to the walls of cancerous cells, and those cells had died. The healthy cells were unaffected.
For years, he tinkered with the protein, building a new molecule with a remarkable talent. No matter the variety of cancer, no matter where in the body, cells treated with the molecule died.
Now, after years of work and trials using animals, the FDA has approved human trials for the treatment. BXQ-350 which owes its name to its discoverer Xiaoyang Qi began phase I human testing in 2016. Patient No. 1 who is suffering from brain cancer had been given a prognosis of 17 months to live with this particular kind of brain cancer.
By the springs of 2018, patient No. 1 had lived 4 ½ years with glioblastoma multiforme. Though the results have been promising, doctors are well aware that the battle is far from over. The trails are continuing for BXQ-350 and because of its early apparent success has been approved for phase II trials and trials on children to begin.
Too early to tell but there’s always hope that this may turn into something good.